BeOne Medicines (NASDAQ:ONC – Get Free Report) and Mannatech (NASDAQ:MTEX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Analyst Ratings
This is a summary of current recommendations and price targets for BeOne Medicines and Mannatech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 1 | 1 | 13 | 0 | 2.80 |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
BeOne Medicines presently has a consensus target price of $378.43, suggesting a potential upside of 11.18%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, equities research analysts clearly believe BeOne Medicines is more favorable than Mannatech.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $3.81 billion | 9.80 | -$644.79 million | $0.51 | 667.41 |
| Mannatech | $117.87 million | 0.12 | $2.49 million | ($0.86) | -8.66 |
Mannatech has lower revenue, but higher earnings than BeOne Medicines. Mannatech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares BeOne Medicines and Mannatech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 1.38% | 5.52% | 3.17% |
| Mannatech | -1.50% | -22.75% | -4.75% |
Risk & Volatility
BeOne Medicines has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
Summary
BeOne Medicines beats Mannatech on 11 of the 14 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
